{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:04:20Z","timestamp":1791057860735,"version":"4.1.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1097\/01.ju.0000073852.24341.4a","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T22:15:08Z","timestamp":1069193708000},"page":"964-969","source":"Crossref","is-referenced-by-count":240,"title":["Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder Cancer"],"prefix":"10.1097","volume":"170","author":[{"given":"ANDREAS","family":"B\u00d6HLE","sequence":"first","affiliation":[{"name":"From the HELIOS Agnes Karll Hospital (AB), Bad Schwartau and Division of Immunotherapy, Department of Immunology, Research Center Borstel (SB), Borstel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SVEN","family":"BRANDAU","sequence":"additional","affiliation":[{"name":"From the HELIOS Agnes Karll Hospital (AB), Bad Schwartau and Division of Immunotherapy, Department of Immunology, Research Center Borstel (SB), Borstel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1097\/01.ju.0000073852.24341.4a_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00184040","article-title":"Strategy for improving therapy of superficial bladder cancer","volume":"9","author":"Ratliff","year":"1991","journal-title":"World J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0952-7915(93)90128-F","article-title":"Non-antibody immunotherapy of cancer","volume":"5","author":"Chapman","year":"1993","journal-title":"Curr Opin Immunol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/1078-1439(95)00041-F","article-title":"Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder","volume":"1","author":"Lamm","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(01)61607-0","article-title":"5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","article-title":"Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer","volume":"6","author":"Herr","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib8","series-title":"Optimal Therapy for Patients With High-Risk Superficial Bladder Cancer\u2014Controversy and Consensus. Proceedings of the First L\u00fcbeck Symposium on Bladder Cancer, L\u00fcbeck, Germany, May 31, 1997","first-page":"45","article-title":"Surgical therapy of high-risk bladder carcinoma. Transurethral resection (TUR) alone vs adjuvant BCG","author":"Herr","year":"1997"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib11","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1128\/jb.178.5.1274-1282.1996","article-title":"Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis","volume":"178","author":"Mahairas","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib12","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","article-title":"Comparative genomics of BCG vaccines by whole-genome DNA microarray","volume":"284","author":"Behr","year":"1999","journal-title":"Science"},{"issue":"suppl.","key":"10.1097\/01.ju.0000073852.24341.4a_bib13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000052388","article-title":"Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use","volume":"37","author":"Schamhart","year":"2000","journal-title":"Eur Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib14","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","article-title":"Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall","volume":"147","author":"Prescott","year":"1992","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0022-5347(17)45922-2","article-title":"Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer","volume":"135","author":"Lage","year":"1986","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00941903","article-title":"Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer","volume":"25","author":"de Boer","year":"1997","journal-title":"Urol Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib17","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64210-1","article-title":"Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression","volume":"158","author":"Thalmann","year":"1997","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0022-5347(01)63835-7","article-title":"Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis","volume":"159","author":"Jackson","year":"1998","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","article-title":"Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy","volume":"99","author":"Jackson","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0022-5347(17)39713-6","article-title":"Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy","volume":"144","author":"Prescott","year":"1990","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib22","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0022-5347(17)45142-1","article-title":"Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG","volume":"136","author":"Haaff","year":"1986","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/1043-4666(90)90013-J","article-title":"Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma","volume":"2","author":"Bohle","year":"1990","journal-title":"Cytokine"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib25","first-page":"179","article-title":"Production of IL-5, a classical TH2 cytokine, following bacillus Calmette-Gu\u00e9rin immunotherapy of bladder cancer","volume":"9","author":"Alexandroff","year":"1996","journal-title":"Int J Oncol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0090-4295(98)00188-5","article-title":"Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10","volume":"52","author":"Poppas","year":"1998","journal-title":"Urology"},{"issue":"suppl.","key":"10.1097\/01.ju.0000073852.24341.4a_bib27","first-page":"114","article-title":"BCG potentiates human chemokine induction in vivo and in vitro","volume":"165","author":"Chen","year":"2001","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0022-5347(17)39365-5","article-title":"Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall","volume":"144","author":"B\u00f6hle","year":"1990","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","article-title":"Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis","volume":"19","author":"de Boer","year":"1991","journal-title":"Urol Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jcp.47.4.309","article-title":"Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy","volume":"47","author":"Jackson","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib31","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/1097-0142(19891001)64:7<1447::AID-CNCR2820640715>3.0.CO;2-Y","article-title":"Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"64","author":"Fleischmann","year":"1989","journal-title":"Cancer"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"de Reijke","year":"1996","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib33","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of Interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib34","first-page":"2918","article-title":"Intravesical and systemic chemotherapy of murine bladder cancer","volume":"37","author":"Soloway","year":"1977","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib35","first-page":"2834","article-title":"Optimizing syngeneic orthotopic murine bladder cancer (MB49)","volume":"59","author":"Gunther","year":"1999","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib36","first-page":"1762","article-title":"Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin","volume":"47","author":"Ratliff","year":"1987","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R","article-title":"Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity","volume":"86","author":"Zhao","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","article-title":"Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement of the expression of an antitumor response","volume":"85","author":"Kavoussi","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-5347(17)43909-7","article-title":"Requirement of a thymus dependent immune response for BCG-mediated antitumor activity","volume":"137","author":"Ratliff","year":"1987","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib40","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","article-title":"T-cell subsets required for intravesical BCG immunotherapy for bladder cancer","volume":"150","author":"Ratliff","year":"1993","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z","article-title":"NK cells are essential for effective BCG immunotherapy","volume":"92","author":"Brandau","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF01534428","article-title":"Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy","volume":"39","author":"McAveney","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2249.1995.tb03599.x","article-title":"Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin","volume":"100","author":"Shin","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib44","first-page":"350","article-title":"Role of IFN-gamma and IL-10 in immunotherapy of bladder cancer with Mycobacterium bovis BCG","volume":"203","author":"Brandau","year":"2000","journal-title":"Immunobiology"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib45","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0022-5347(17)37582-1","article-title":"The inhibitory effects of interferon gamma on the growth of bladder cancer cells","volume":"147","author":"Hawkyard","year":"1992","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01517042","article-title":"Induction of bacillus Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro","volume":"37","author":"Thanhauser","year":"1993","journal-title":"Cancer Immunol Immunother"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00296835","article-title":"Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG)","volume":"21","author":"de Reijke","year":"1993","journal-title":"Urol Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0022-5347(01)67113-1","article-title":"Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy","volume":"154","author":"Esuvaranathan","year":"1995","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01517219","article-title":"Antiproliferative effects of bacillus Calmette-Guerin and Interferon alpha-2b on human bladder cancer cells in vitro","volume":"41","author":"Pryor","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib50","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/bjc.1995.155","article-title":"Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing","volume":"71","author":"Pryor","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/1097-0142(19920115)69:2<537::AID-CNCR2820690242>3.0.CO;2-3","article-title":"Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer","volume":"69","author":"Mizutani","year":"1992","journal-title":"Cancer"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF01520291","article-title":"The induction of bacillus-Calmette-Gu\u00e9rin-activated killer cells requires the presence of monocytes and T-helper type-1 cells","volume":"40","author":"Thanh\u00e4user","year":"1995","journal-title":"Cancer Immunol Immunother"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib53","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000052497","article-title":"Activation of natural killer cells by Bacillus Calmette-Guerin","volume":"39","author":"Brandau","year":"2001","journal-title":"Eur Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib54","first-page":"3729","article-title":"Perforin-mediated lysis of tumor cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated killer cells","volume":"6","author":"Brandau","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib55","first-page":"476","article-title":"BCG-immunotherapy of superficial bladder cancer: BCG-induced activation of MNCs is regulated by cytokines","volume":"36","author":"Reiss","year":"1999","journal-title":"Eur Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib56","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.4049\/jimmunol.163.8.4246","article-title":"Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin","volume":"163","author":"O'Donnell","year":"1999","journal-title":"J Immunol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib57","first-page":"61","article-title":"Interleukin-12 regulates the production of Bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner","volume":"50","author":"Mendez-Samperio","year":"1999","journal-title":"Scand J Immunol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib58","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"J Immunol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib59","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0022-5347(01)65748-3","article-title":"Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer","volume":"156","author":"Chin","year":"1996","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0022-5347(17)46976-X","article-title":"Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results","volume":"134","author":"Kelley","year":"1985","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib61","first-page":"1611","article-title":"Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity","volume":"43","author":"Shapiro","year":"1983","journal-title":"Cancer Res"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib62","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical \u03b1-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J Urol"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib63","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0090-4295(96)00375-5","article-title":"Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer","volume":"48","author":"Stricker","year":"1996","journal-title":"Urology"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0094-0143(05)70242-1","article-title":"Interleukin-12. Opportunities for the treatment of bladder cancer","volume":"27","author":"Clinton","year":"2000","journal-title":"Urol Clin N Am"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib65","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1128\/IAI.62.6.2508-2514.1994","article-title":"Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes","volume":"62","author":"O'Donnell","year":"1994","journal-title":"Infect Immun"},{"key":"10.1097\/01.ju.0000073852.24341.4a_bib66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","article-title":"Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity","volume":"123","author":"Luo","year":"2001","journal-title":"Clin Exp Immunol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534705632880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534705632880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1097\/01.ju.0000073852.24341.4a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T13:41:45Z","timestamp":1682602905000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1097\/01.ju.0000073852.24341.4a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,9]]}},"alternative-id":["10.1097\/01.ju.0000073852.24341.4a"],"URL":"https:\/\/doi.org\/10.1097\/01.ju.0000073852.24341.4a","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}